VulnerabilityModified
CVE-2022-48226
During installation, an EXE gets executed out of C:\Windows\Temp.
HIGH 7.8EPSS 0.18%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.18%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
An issue was discovered in Acuant AcuFill SDK before 10.22.02.03. During installation, an EXE gets executed out of C:\Windows\Temp. A standard user can create the path file ahead of time and obtain elevated code execution. Permissions need to be modified to prevent manipulation.
- CVSS 3.1
- 7.8 HIGHCVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 0.18% probability · 8th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-269
- Affected
- gbgplc/acuant acufill sdk
- Source
- cve@mitre.org
References
- https://acuant.comNot Applicable
- https://hackandpwn.com/disclosures/CVE-2022-48226.pdfThird Party Advisory
- https://acuant.comNot Applicable
- https://hackandpwn.com/disclosures/CVE-2022-48226.pdfThird Party Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.